Meeting
2023 ASCO Annual Meeting
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
Presenter
Dirk Schadendorf, MD
University Hospital Essen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04657991
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9531)
DOI
10.1200/JCO.2023.41.16_suppl.9531
Abstract #
9531
Poster Bd #
294
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
Speaker: Sajeve Samuel Thomas
Videos & Slides
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
Speaker: Erika Richtig
Videos & Slides
2021 ASCO Annual Meeting
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
Speaker: Erika Richtig
Videos & Slides
2024 ASCO Annual Meeting
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.
Speaker: Sapna Pradyuman Patel, MD